SillaJen, Inc.
π°π·South Korea
BAL0891 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT05768932
- Locations
- π°π·
Seoul National University Hospital, Seoul, Korea, Republic of
π°π·Korean University Anam Hospital, Seoul, Korea, Republic of
πΊπΈOHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT03294083
- Locations
- π¦πΊ
Site 2632 Flinders Medical Centre, Bedford Park, Australia
πΊπΈSite 2643 Washington University, Saint Louis, Missouri, United States
π°π·Site 2612 Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 459
- Registration Number
- NCT02562755
- Locations
- π¨π³
Site No. 8306, Taichung, Taiwan
πΉπSite No. 8505, Bangkok, Thailand
πΉπSite No. 8503, Chiang Mai, Thailand
Β© Copyright 2024. All Rights Reserved by MedPath